Biotechnology Finance Director

FD Capital recruits Finance Directors and CFOs for UK biotechnology and life sciences businesses — from early-stage drug discovery and diagnostics companies through to clinical-stage biotech, medical device manufacturers and commercial-stage life sciences groups. Biotechnology finance is a specialist area: the combination of R&D accounting complexity, clinical milestone-based funding structures, revenue recognition challenges for licensing agreements and royalties, and the regulatory and investor reporting requirements of the sector create a finance leadership brief that is materially different from general commercial finance. Adrian Lawrence FCA, founder of FD Capital and a Fellow of the ICAEW, leads our senior finance recruitment practice.

Call 020 3287 9501 or email recruitment@fdcapital.co.uk. Shortlists within three to five working days.

Adrian Lawrence FCA — Founder, FD Capital
Fellow of the ICAEW | ICAEW-Registered Practice | Life sciences and biotechnology finance placements since 2018

Biotechnology Finance Directors operate at the intersection of science and capital markets in a way that very few other senior finance roles require. They need to translate complex R&D programmes into financial models that make sense to institutional investors, structure the accounting treatment of research grants, milestone payments and collaboration agreements, and manage investor relations through clinical trial readouts and regulatory events that can move the company’s valuation materially overnight. FD Capital’s life sciences finance network includes Finance Directors and CFOs who have worked across the full spectrum — pre-revenue drug discovery companies, clinical-stage biotechs raising Series B and C, and commercial-stage life sciences groups with complex product revenue recognition.

What Makes Biotechnology Finance Different

R&D accounting and IFRS complexity

The accounting treatment of research and development expenditure under IFRS is one of the most technically demanding areas of biotechnology finance — determining when research expenditure must be expensed and when development costs may be capitalised as intangible assets, assessing the ongoing impairment of capitalised development assets as clinical programmes progress or fail, and managing the disclosures required by IAS 38. In addition, biotechnology companies frequently receive R&D tax credits under the UK’s R&D relief schemes, and the interaction between the accounting treatment of qualifying expenditure, the tax credit claims, and the financial model that investors are using to value the pipeline requires a Finance Director who understands all three simultaneously.

Grant accounting and collaborative revenue

Many early-stage UK biotechnology companies receive non-dilutive funding from Innovate UK, UKRI, Wellcome Trust, or international grant bodies alongside equity financing. The accounting treatment of grants under IAS 20 — distinguishing between grants related to assets (deducted from the carrying amount of the asset or recognised as deferred income) and grants related to income (matched to the expenditure they fund) — is straightforward in principle but complex in practice when grants are structured as milestone-based tranches linked to specific R&D deliverables. The Finance Director must ensure grant accounting is correct not only for financial reporting purposes but for the grant body’s reporting requirements and audit process.

Milestone and licensing revenue recognition

Commercial-stage biotechnology companies and those with licensing agreements often have revenue streams structured as upfront licence fees, development milestones, regulatory milestones and royalties — all with different timing, conditionality and accounting treatment under IFRS 15. The determination of performance obligations, transaction prices and the timing of revenue recognition for complex multi-element licensing arrangements is a specialist area that requires a Finance Director with direct prior experience of accounting for these structures. Errors in revenue recognition for biotech licensing deals have historically been a significant source of accounting restatements and investor relations damage.

Investor relations and scientific narrative

Biotechnology Finance Directors work alongside the CEO and Chief Scientific Officer in investor relations — communicating the financial implications of clinical programmes, modelling the value of the pipeline under different probability-adjusted scenarios, and presenting to specialist healthcare investors and generalist institutional investors who have varying levels of scientific literacy. The ability to translate between scientific milestones and financial implications is a skill that distinguishes a Finance Director who has worked in biotech from one who has worked in other sectors.

Cash runway management

For pre-revenue and clinical-stage biotechnology companies, cash runway — the period for which the business can sustain operations at its current burn rate — is the most critical financial metric. The Finance Director is responsible for managing burn rate against the clinical programme’s cash requirements, maintaining an accurate 12–18 month cash forecast, and ensuring the business initiates its next fundraising round with sufficient lead time to avoid distress financing. This requires not only financial modelling capability but a clear understanding of the clinical programme timeline and its dependencies, which is only achievable for Finance Directors who have spent meaningful time in the biotech sector.

Biotechnology Finance Director Roles FD Capital Places

Pre-revenue and clinical-stage biotech (Series A–C)

Finance Directors for early and clinical-stage biotechnology companies focus primarily on cash management, investor reporting, grant accounting, R&D cost tracking and fundraising support. The Finance Director at this stage often serves as both the CFO equivalent and the Head of Finance, managing a small internal finance team and working closely with the company’s auditors and tax advisers on the technical accounting issues specific to the sector. FD Capital places both permanent and fractional Finance Directors for businesses at this stage — the fractional model is particularly well-suited to pre-revenue biotechs where the finance workload is significant but does not yet justify a full-time appointment.

Commercial-stage life sciences

Finance Directors for commercial-stage life sciences businesses have a broader mandate — managing product revenue recognition, sales force cost control, reimbursement and pricing strategy, and the financial integration of acquisitions or licensing deals alongside the investor relations and regulatory reporting requirements of the sector. These appointments typically require a Finance Director with both sector experience and scale experience — someone who has managed the transition from R&D-phase accounting to commercial revenue recognition is specifically valuable at this stage.

CFO for listed and pre-IPO biotech

For biotechnology companies that are listed on AIM, the London Main Market, or planning an IPO, the CFO appointment requires compliance with UK public company financial reporting requirements alongside the sector-specific accounting expertise. FD Capital’s CFO Executive Search practice places at this level — candidates with AIM or Main Market CFO experience in life sciences are a specialist pool that FD Capital accesses through its senior finance network.

Biotechnology Finance Director Salary Guide UK 2026

Stage / Role	Typical Salary	Equity / Bonus
FD — pre-revenue / Series A–B biotech	£90,000 – £130,000	Share options common; performance bonus
FD — clinical stage / Series C	£110,000 – £150,000	EMI or unapproved options; bonus
CFO — commercial life sciences	£140,000 – £200,000+	Long-term incentive plan; bonus 20–30%
CFO — AIM-listed biotech	£150,000 – £220,000+	LTIP; bonus; pension contribution
Fractional FD — early-stage biotech	£400 – £650/day	Warrants or share options in some cases

Related Life Sciences and Senior Finance Services

Find a Biotechnology Finance Director

FD Capital recruits Finance Directors and CFOs for UK biotechnology and life sciences businesses — pre-revenue, clinical stage and commercial. Permanent, fractional and interim. Candidates with genuine sector experience in R&D accounting, grant management, milestone revenue and biotech investor relations. Shortlists within three to five working days.

📞 020 3287 9501
✉ recruitment@fdcapital.co.uk

Tell Us About Your Requirement →